Calcium D-Glucarate Cuts β-Glucuronidase 56% in 8-Week RCT
WELLNESS

Calcium D-Glucarate Cuts β-Glucuronidase 56% in 8-Week RCT

By Sophie · · Cancer Prevention Research 2025
KO | EN

Calcium D-glucarate (CDG) 1,500mg/day for 8 weeks significantly suppressed β-glucuronidase activity and estrogen reabsorption markers in 90 perimenopausal women, according to 2025 data in Cancer Prevention Research. CDG protects Phase II glucuronide conjugation, accelerating hormone and toxin clearance.

The trial enrolled 90 perimenopausal women across 8 weeks. Results: serum β-glucuronidase activity -56%, 16α-OH estrone concentration -23%, 2-OH/16-OH ratio +1.4x, urinary glucuronide-conjugated estrogen +18% (clearance accelerated), cholesterol -8%. Adverse events limited to mild constipation (8%).

What is CDG

Calcium D-glucarate (CDG) is the calcium salt of D-glucaric acid, found in trace amounts in apples, grapefruit, cruciferous vegetables, and beans. The body converts D-glucaric acid into D-glucaro-1,4-lactone, a potent β-glucuronidase inhibitor. Reaching the 1,500mg+ clinical dose through diet is impossible — supplement form is essential.

Available forms:

  • CDG powder: 1~3g/day divided
  • CDG 500mg capsules
  • Standalone or matrix with DIM·NAC

Multi-target mechanisms

1. β-Glucuronidase suppression — Phase II conjugation defense:

  • Phase II conjugation: liver binds hormones·toxins to glucuronic acid for biliary/urinary excretion
  • Gut bacterial and tissue β-glucuronidase cleaves these conjugates → reabsorption
  • CDG suppresses β-glucuronidase -56% → conjugates preserved
  • Maintained conjugation accelerates hormone, toxin, carcinogen, drug metabolite clearance

2. Estrogen metabolism support:

  • 16α-OH estrone is most susceptible to β-glucuronidase reabsorption
  • CDG protects 16-OH conjugates → reabsorption blocked
  • Synergizes with DIM (DIM acts on Phase I, CDG on Phase II)

3. Carcinogen protection:

  • Supports clearance of BPA, dioxin, heterocyclic amine metabolites
  • Mechanism-supportive rather than clinically definitive

4. Cholesterol·LDL:

  • Bile acid binding modulation → enterohepatic recirculation
  • Meta-analysis LDL -8%

Clinical data

  • Cancer Prevention Research 2025 RCT 90 patients 8 weeks: β-glucuronidase -56%
  • 2024 trial: fibroid patients 12 weeks CDG 1,500mg/day + DIM matrix, volume -18%
  • 2022 trial: menopausal hot flash score -22% (estrogen reabsorption blockade)
  • 2021 trial: colorectal cancer risk markers (butyrate, β-glucuronidase) -32%

Cautions

  • Drug interactions (Phase II acceleration): glucuronidated drugs (acetaminophen, morphine, propranolol, some benzodiazepines) cleared faster → reduced efficacy possible. Physician assessment
  • Constipation: calcium content → some constipation. Magnesium synergy or hydration
  • Kidney stones: calcium + oxalate matrix risk — monitor oxalate intake (spinach, beets, almonds)
  • Pregnancy·lactation: limited data, avoid
  • Thyroid medication: may impair levothyroxine absorption — separate by 4 hours
  • Reassess at 3 months: confirm effect, consider 6-month break
  • Divided dosing: 1,500mg/day = 500mg × 3 with meals

Synergy matrix

  • CDG + DIM: Phase I + Phase II matrix
  • CDG + NAC + Glutathione: Phase II conjugation matrix
  • CDG + Manganese + B6: PMS hormone matrix
  • CDG + Silymarin + Artichoke: liver support matrix

Consumer message

For hormone balance and liver detox, hormone blockers or single-target supplements only address one route. Calcium D-glucarate defends Phase II conjugation (β-glucuronidase -56%) to accelerate hormone, toxin, and carcinogen clearance. Caveats: drug interactions (acetaminophen, morphine, thyroid meds), constipation risk, oxalate kidney stone considerations, pregnancy avoidance, dietary insufficiency, divided dosing required. Pairs with DIM as a Phase I+II dual approach. A core molecule in tetrapod’s spring 2026 hormone and detox matrix.